124P - Tandem repeat variation in HIC1 gene predicts outcome for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Anticancer Agents
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Biological Therapy
Presenter Satoshi Okazaki
Citation Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363
Authors S. Okazaki1, F. Loupakis2, M. Schirripa3, S. Cao4, W. Zhang3, D. Yang4, Y. Ning3, M.D. Berger3, Y. Miyamoto3, M. Suenaga3, R. Gopez3, B.B. Borelli5, C. Cremolini5, A. Falcone5, S. Lonardi2, L. Salvatore5, H. Uetake6, T. Kawano1, T. Helentjaris7, H. Lenz3
  • 1Gastrointestinal Surgery, Tokyo Medical and Dental University, 1138519 - Tokyo/JP
  • 2Oncologia Medica 1, Istituto Oncologico Veneto IRCCS, Padova/IT
  • 3Department Of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles/US
  • 4Department Of Preventive Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles/US
  • 5Unit Of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, 56126 - Pisa/IT
  • 6Specialized Surgeries, Tokyo Medical and Dental University, Tokyo/JP
  • 7Bio5 And Department Of Plant Sciences, University of Arizona, Tucson/US



HIC1 (Hypermethylated in Cancer 1) is a transcription repressor, which cooperates with several partners to suppress the expression of multiple target genes. Among HIC1 targets, SIRT1 (Sirtuin1) plays a critical role in promoting the nucleotide excision repair (NER) pathway, which is the main oxaliplatin-induced damage repair system. HIC1 expression might be influenced by the number of variations in a tandemly-repeated sequence, situated close to the promoter region. We tested the hypothesis that variable number of tandem repeat (TR) in HIC1 will be associated with outcome in metastatic colorectal cancer patients (mCRC pts) receiving 1st-line chemotherapy with oxaliplatin.


This study enrolled 3 independent cohorts. Pts treated with FOLFOXIRI + bevacizumab in the phase III TRIBE study served as a training set (TRIBE-B cohort, n = 218). Pts receiving FOLFOXIRI + bevacizumab in the phase II MOMA study served as a validation set (MOMA cohort, n = 176). Pts treated without oxaliplatin (FOLFIRI + bevacizumab) in the TRIBE study served as a control set (TRIBE-A cohort, n = 215). Genomic DNA was isolated from blood samples. Variations in the number of TR were analyzed by PCR and Gel electrophoresis, and tested for the association with PFS and OS.


Main patients characteristics' were the following: TRIBE-A; M/F 60/40%, median age 60, TRIBE-B; M/F 60/40%, median age 60, MOMA; M/F 57/43%, median age 61. Median follow-up times were 49.9, 48.0, and 25.3 months, respectively. Pts with number of TR ≤4 or ≥5 were 90/10% (TRIBE-A), 91/9% (TRIBE-B), and 95/5% (MOMA), respectively. In the training cohort, pts with TRs ≥5 showed a significantly shorter PFS compared to those with TRs ≤4 (9.5 vs. 11.6 mo, HR 1.93, P = 0.012), which retained statistical significance in multivariate analysis (HR 2.00, 95%CI: 1.13-3.54, P = 0.018). This preliminary association was confirmed in the validation cohort, and pts with TRs ≥5 showed a worse PFS compared to others (7.9 vs. 9.8 mo, HR 1.85, P = 0.044). This correlation was not observed in the control cohort.


Our findings suggest that variable number of TRs in HIC1 could be a predictive marker for oxaliplatin-containing chemotherapy in mCRC pts.

Clinical trial identification

Legal entity responsible for the study

University of Southern California


National Institute of Health


All authors have declared no conflicts of interest.